{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:30:40Z","timestamp":1794490240814,"version":"4.9.1"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Korea Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["23194MFDS086"],"award-info":[{"award-number":["23194MFDS086"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008783","name":"National Research Council of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008783","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["CAP23053-000"],"award-info":[{"award-number":["CAP23053-000"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejmech.2025.118485","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T02:27:35Z","timestamp":1765592855000},"page":"118485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Direct small-molecule inhibitors of the Keap1-Nrf2 protein-protein interaction: Scaffold evolution, PROTAC strategies, and therapeutic implications"],"prefix":"10.1016","volume":"303","author":[{"given":"Hwangeui","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2257-0798","authenticated-orcid":false,"given":"Sumi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118485_bib1","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s00204-023-03562-9","article-title":"Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging","volume":"97","author":"Jomova","year":"2023","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.ejmech.2025.118485_bib2","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1245049","article-title":"Role of ROS and RNS sources in physiological and pathological conditions","volume":"2016","author":"Di Meo","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ejmech.2025.118485_bib3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/35041687","article-title":"Oxidants, oxidative stress and the biology of ageing","volume":"408","author":"Finkel","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118485_bib4","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1089\/ars.2020.8161","article-title":"Interplay between reactive oxygen\/reactive nitrogen species and metabolism in vascular biology and disease","volume":"34","author":"Ushio-Fukai","year":"2021","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.ejmech.2025.118485_bib5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev-pharmtox-011112-140320","article-title":"Role of Nrf2 in oxidative stress and toxicity","volume":"53","author":"Ma","year":"2013","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2025.118485_bib6","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.devcel.2007.12.002","article-title":"Keap1\/Nrf2 signaling regulates oxidative stress tolerance and lifespan in drosophila","volume":"14","author":"Sykiotis","year":"2008","journal-title":"Dev. Cell"},{"key":"10.1016\/j.ejmech.2025.118485_bib7","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.freeradbiomed.2009.07.035","article-title":"Nrf2:INrf2 (Keap1) signaling in oxidative stress","volume":"47","author":"Kaspar","year":"2009","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejmech.2025.118485_bib8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.tibs.2024.12.010","article-title":"Regulating Nrf2 activity: ubiquitin ligases and signaling molecules in redox homeostasis","volume":"50","author":"Hayes","year":"2025","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2025.118485_bib9","doi-asserted-by":"crossref","first-page":"10941","DOI":"10.1128\/MCB.24.24.10941-10953.2004","article-title":"Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex","volume":"24","author":"Zhang","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118485_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00099-20","article-title":"The molecular mechanisms regulating the KEAP1-NRF2 pathway","volume":"40","author":"Baird","year":"2020","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118485_bib11","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s42003-021-02100-6","article-title":"Molecular basis for the disruption of Keap1\u2013Nrf2 interaction via Hinge & Latch mechanism","volume":"4","author":"Horie","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejmech.2025.118485_bib12","doi-asserted-by":"crossref","first-page":"8137","DOI":"10.1128\/MCB.23.22.8137-8151.2003","article-title":"Distinct cysteine residues in Keap1 are required for Keap1-Dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress","volume":"23","author":"Zhang","year":"2003","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118485_bib13","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00044-020-02539-y","article-title":"Nrf2 activation through the inhibition of Keap1\u2013Nrf2 protein\u2013protein interaction","volume":"29","author":"Lee","year":"2020","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2025.118485_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116104","article-title":"Structural modification of C2-substituents on 1,4-bis(arylsulfonamido)benzene or naphthalene-N,N\u2032-diacetic acid derivatives as potent inhibitors of the Keap1-Nrf2 protein-protein interaction","volume":"265","author":"Lee","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib15","doi-asserted-by":"crossref","first-page":"7511","DOI":"10.1128\/MCB.00753-07","article-title":"Different electrostatic potentials define ETGE and DLG motifs as Hinge and latch in oxidative stress response","volume":"27","author":"Tong","year":"2007","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118485_bib16","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1128\/MCB.26.8.2887-2900.2006","article-title":"Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model","volume":"26","author":"Tong","year":"2006","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118485_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1042\/BJ20090471","article-title":"Cul3-mediated Nrf2 ubiquitination and antioxidant response element (ARE) activation are dependent on the partial molar volume at position 151 of Keap1","volume":"422","author":"Eggler","year":"2009","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2025.118485_bib18","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1021\/tx700302s","article-title":"Covalent modification at Cys151 dissociates the electrophile sensor Keap1 from the ubiquitin ligase CUL3","volume":"21","author":"Rachakonda","year":"2008","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2025.118485_bib19","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1305687110","article-title":"Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein complex","volume":"110","author":"Baird","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2025.118485_bib20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00204-011-0674-5","article-title":"The cytoprotective role of the Keap1\u2013Nrf2 pathway","volume":"85","author":"Baird","year":"2011","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.ejmech.2025.118485_bib21","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.apsb.2015.05.008","article-title":"Discovery of direct inhibitors of Keap1\u2013Nrf2 protein\u2013protein interaction as potential therapeutic and preventive agents","volume":"5","author":"Abed","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.118485_bib22","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/med.21257","article-title":"Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents","volume":"32","author":"Magesh","year":"2012","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2025.118485_bib23","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/1873-3468.12964","article-title":"Role of mitochondrial ROS in the brain: from physiology to neurodegeneration","volume":"592","author":"Angelova","year":"2018","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2025.118485_bib24","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.redox.2017.07.006","article-title":"NRF2 deficiency replicates transcriptomic changes in Alzheimer's patients and worsens APP and TAU pathology","volume":"13","author":"Rojo","year":"2017","journal-title":"Redox Biol."},{"key":"10.1016\/j.ejmech.2025.118485_bib25","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1073\/pnas.0813361106","article-title":"Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte","volume":"106","author":"Chen","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2025.118485_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011838","article-title":"Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1","volume":"5","author":"Innamorato","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118485_bib27","doi-asserted-by":"crossref","first-page":"13574","DOI":"10.1523\/JNEUROSCI.4099-08.2008","article-title":"Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis","volume":"28","author":"Vargas","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejmech.2025.118485_bib28","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/toxsci\/kfp274","article-title":"The absence of the pro-antioxidant transcription factor Nrf2 exacerbates experimental autoimmune encephalomyelitis","volume":"114","author":"Johnson","year":"2009","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ejmech.2025.118485_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004253","article-title":"Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia","volume":"4","author":"Paupe","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118485_bib30","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1089\/ars.2012.4537","article-title":"Frataxin deficiency leads to defects in expression of antioxidants and Nrf2 expression in Dorsal root ganglia of the Friedreich's Ataxia YG8R Mouse model","volume":"19","author":"Shan","year":"2013","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.ejmech.2025.118485_bib31","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1089\/ars.2012.5149","article-title":"Reactive oxygen species in inflammation and tissue injury, antioxid","volume":"20","author":"Mittal","year":"2013","journal-title":"Redox Signal."},{"key":"10.1016\/j.ejmech.2025.118485_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11624","article-title":"Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription","volume":"7","author":"Kobayashi","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118485_bib33","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1172\/JCI200421146","article-title":"Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke\u2013induced emphysema in mice","volume":"114","author":"Rangasamy","year":"2004","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2025.118485_bib34","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1378\/chest.12-2664","article-title":"Oxidative stress in COPD","volume":"144","author":"Kirkham","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.ejmech.2025.118485_bib35","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1365-2443.2005.00905.x","article-title":"Nrf2-deficient mice are highly susceptible to cigarette smoke-induced emphysema","volume":"10","author":"Iizuka","year":"2005","journal-title":"Genes Cells"},{"key":"10.1016\/j.ejmech.2025.118485_bib36","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1096\/fj.03-1127fje","article-title":"The transcription factor NRF2 protects against pulmonary fibrosis","volume":"18","author":"Cho","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.ejmech.2025.118485_bib37","article-title":"The Nrf2 pathway in liver diseases","volume":"10","author":"Zhou","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2025.118485_bib38","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.biopha.2018.05.135","article-title":"Curcumin regulates endogenous and exogenous metabolism via Nrf2-FXR-LXR pathway in NAFLD mice","volume":"105","author":"Yan","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.118485_bib39","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/labinvest.2008.75","article-title":"The Nrf2 transcription factor protects from toxin-induced liver injury and fibrosis","volume":"88","author":"Xu","year":"2008","journal-title":"Lab. Invest."},{"key":"10.1016\/j.ejmech.2025.118485_bib40","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/ki.2012.439","article-title":"Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease","volume":"83","author":"Ruiz","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejmech.2025.118485_bib41","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202503330","article-title":"Efficacy of Nrf2 activation in a proteinuric Alport syndrome mouse model","volume":"8","author":"Kaseda","year":"2025","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.ejmech.2025.118485_bib42","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1093\/ndt\/gft022","article-title":"Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy","volume":"28","author":"Aminzadeh","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejmech.2025.118485_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1184079","article-title":"Nrf2 signaling pathway: current status and potential therapeutic targetable role in human cancers","volume":"13","author":"Lin","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2025.118485_bib44","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.freeradbiomed.2014.11.009","article-title":"Dual roles of NRF2 in tumor prevention and progression: possible implications in cancer treatment","volume":"79","author":"Moon","year":"2015","journal-title":"Free Radical Biol. Med."},{"key":"10.1016\/j.ejmech.2025.118485_bib45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/carcin\/bgp231","article-title":"Nrf2: friend or foe for chemoprevention?","volume":"31","author":"Kensler","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejmech.2025.118485_bib46","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.molmed.2016.05.002","article-title":"The dual roles of NRF2 in cancer","volume":"22","author":"Menegon","year":"2016","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejmech.2025.118485_bib47","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12964-022-00906-3","article-title":"An update of Nrf2 activators and inhibitors in cancer prevention\/promotion","volume":"20","author":"Pouremamali","year":"2022","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejmech.2025.118485_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116822","article-title":"NRF2 inhibitors: recent progress, future design and therapeutic potential","volume":"279","author":"Lv","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib49","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1038\/sj.emboj.7601243","article-title":"Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling","volume":"25","author":"Lo","year":"2006","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2025.118485_bib50","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1021\/jm5000529","article-title":"Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis","volume":"57","author":"Jiang","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib51","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/med.21925","article-title":"KEAP1-NRF2 protein\u2013protein interaction inhibitors: design, pharmacological properties and therapeutic potential","volume":"43","author":"Crisman","year":"2023","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2025.118485_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103800","article-title":"Advances in developing noncovalent small molecules targeting Keap1","volume":"28","author":"Barreca","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.118485_bib53","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.tips.2022.12.003","article-title":"Advances and challenges in therapeutic targeting of NRF2","volume":"44","author":"Dinkova-Kostova","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2025.118485_bib54","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/9372182","article-title":"Activators and inhibitors of NRF2: a review of their potential for clinical development","volume":"2019","author":"Robledinos-Anton","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ejmech.2025.118485_bib55","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1111\/febs.15485","article-title":"Structural insights into the multiple binding modes of dimethyl fumarate (DMF) and its analogs to the Kelch domain of Keap1","volume":"288","author":"Unni","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2025.118485_bib56","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/1756285614564152","article-title":"Dimethyl fumarate in the treatment of relapsing\u2013remitting multiple sclerosis: an overview","volume":"8","author":"Bomprezzi","year":"2015","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.ejmech.2025.118485_bib57","first-page":"883","article-title":"Efficacy of dimethyl fumarate in young adults with relapsing-remitting multiple sclerosis: analysis of the DEFINE, CONFIRM, and ENDORSE studies, neurol","volume":"12","author":"Amezcua","year":"2023","journal-title":"Therapy"},{"key":"10.1016\/j.ejmech.2025.118485_bib58","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1177\/13524585211037909","article-title":"Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: final ENDORSE study results","volume":"28","author":"Gold","year":"2021","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.ejmech.2025.118485_bib59","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1021\/tx100389r","article-title":"Modification of Keap1 cysteine residues by sulforaphane","volume":"24","author":"Hu","year":"2011","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2025.118485_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.116797","article-title":"Sulforaphane: an emerging star in neuroprotection and neurological disease prevention","volume":"233","author":"Wu","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118485_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1168321","article-title":"Anticancer properties of sulforaphane: current insights at the molecular level","volume":"13","author":"Asif Ali","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2025.118485_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098896","article-title":"Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO","volume":"9","author":"Cleasby","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118485_bib63","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jprot.2014.05.007","article-title":"Identification and quantification of the basal and inducible Nrf2-dependent proteomes in mouse liver: biochemical, pharmacological and toxicological implications","volume":"108","author":"Walsh","year":"2014","journal-title":"J. Proteonomics"},{"key":"10.1016\/j.ejmech.2025.118485_bib64","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118485_bib65","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1159\/000529471","article-title":"The CARDINAL trial of bardoxolone methyl in Alport syndrome: when marketing interests prevail over patients clinical needs","volume":"147","author":"Ruggenenti","year":"2023","journal-title":"Nephron"},{"key":"10.1016\/j.ejmech.2025.118485_bib66","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.molmed.2023.12.002","article-title":"Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for friedreich ataxia","volume":"30","author":"Pilotto","year":"2024","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejmech.2025.118485_bib67","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.29286","article-title":"Efficacy of omaveloxolone in Friedreich's Ataxia: delayed-start analysis of the MOXIe extension","volume":"38","author":"Lynch","year":"2023","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejmech.2025.118485_bib68","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ana.25934","article-title":"Safety and efficacy of omaveloxolone in Friedreich Ataxia (MOXIe study)","volume":"89","author":"Lynch","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejmech.2025.118485_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2020.100079","article-title":"NRF2 activator A-1396076 ameliorates inflammation in autoimmune disease models by inhibiting antigen dependent T cell activation","volume":"4","author":"Goess","year":"2021","journal-title":"J. Transl. Autoimmun."},{"key":"10.1016\/j.ejmech.2025.118485_bib70","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1016\/j.bmcl.2013.03.013","article-title":"Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction","volume":"23","author":"Hu","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118485_bib71","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/jbt.21693","article-title":"Activation of NRF2 signaling in HEK293 cells by a first-in-class direct KEAP1-NRF2 inhibitor","volume":"29","author":"Wen","year":"2015","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.ejmech.2025.118485_bib72","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/cmdc.201300525","article-title":"Binding mode and structure\u2013activity relationships around direct inhibitors of the Nrf2\u2013Keap1 complex","volume":"9","author":"Jnoff","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118485_bib73","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1021\/acsmedchemlett.9b00594","article-title":"Combined peptide and small-molecule approach toward nonacidic THIQ inhibitors of the KEAP1\/NRF2 interaction","volume":"11","author":"Ontoria","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118485_bib74","series-title":"Therapeutic Compounds, WO2020084300 A1","author":"Blaney","year":"2020"},{"key":"10.1016\/j.ejmech.2025.118485_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126852","article-title":"Design, synthesis and identification of novel, orally bioavailable non-covalent Nrf2 activators","volume":"30","author":"Ma","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118485_bib76","doi-asserted-by":"crossref","first-page":"19247","DOI":"10.1021\/acs.jmedchem.4c01687","article-title":"Discovery of propionic acid derivatives with a 5-THIQ core as potent and orally bioavailable Keap1\u2013Nrf2 protein\u2013protein interaction inhibitors for acute kidney injury","volume":"67","author":"Shi","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib77","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1016\/j.bmc.2013.04.019","article-title":"Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism","volume":"21","author":"Marcotte","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib78","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1021\/acs.jmedchem.5b00185","article-title":"Structure\u2013activity and structure\u2013property relationship and exploratory in vivo evaluation of the nanomolar Keap1\u2013Nrf2 protein\u2013protein interaction inhibitor","volume":"58","author":"Jiang","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101266","article-title":"CPUY192018, a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, alleviates renal inflammation in mice by restricting oxidative stress and NF-\u03baB activation","volume":"26","author":"Lu","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.ejmech.2025.118485_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116300","article-title":"Optimization of 1,4-bis(arylsulfonamido)naphthalene-N,N'-diacetic acids as inhibitors of Keap1-Nrf2 protein-protein interaction to suppress neuroinflammation","volume":"44","author":"Abed","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib81","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ejmech.2015.08.049","article-title":"Probing the structural requirements of non-electrophilic naphthalene-based Nrf2 activators","volume":"103","author":"Jain","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib82","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1021\/acsmedchemlett.5b00407","article-title":"Polar recognition group study of Keap1-Nrf2 protein\u2013protein interaction inhibitors","volume":"7","author":"Lu","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118485_bib83","doi-asserted-by":"crossref","first-page":"8029","DOI":"10.1021\/acs.jmedchem.8b01133","article-title":"Replacement of a naphthalene scaffold in Kelch-like ECH-associated protein 1 (KEAP1)\/nuclear factor (erythroid-derived 2)-like 2 (NRF2) inhibitors","volume":"61","author":"Richardson","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib84","doi-asserted-by":"crossref","first-page":"6547","DOI":"10.1021\/acs.jmedchem.9b01074","article-title":"Isoquinoline kelch-like ECH-associated protein 1-Nuclear factor (Erythroid-Derived 2)-like 2 (KEAP1-NRF2) inhibitors with high metabolic stability","volume":"63","author":"Lazzara","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103703","article-title":"The isoquinoline PRL-295 increases the thermostability of Keap1 and disrupts its interaction with Nrf2","volume":"25","author":"Dayalan Naidu","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.ejmech.2025.118485_bib86","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1016\/j.bmcl.2017.10.008","article-title":"Discovery of benzo[g]indoles as a novel class of non-covalent Keap1-Nrf2 protein-protein interaction inhibitor","volume":"27","author":"Yasuda","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118485_bib87","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1080\/14756366.2022.2124408","article-title":"Design, synthesis and evaluation of novel small molecules acting as Keap1-Nrf2 protein-protein interaction inhibitors","volume":"37","author":"Sun","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115343","article-title":"Discovery of disubstituted xylylene derivatives as small molecule direct inhibitors of Keap1-Nrf2 protein-protein interaction","volume":"28","author":"Abed","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib89","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1016\/j.bmcl.2016.10.083","article-title":"Synthesis of Keap1-phosphorylated p62 and Keap1-Nrf2 protein-protein interaction inhibitors and their inhibitory activity","volume":"26","author":"Yasuda","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118485_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114380","article-title":"Structure-activity relationships of 1,4-bis(arylsulfonamido)-benzene or naphthalene-N,N\u2032-diacetic acids with varying C2-substituents as inhibitors of Keap1-Nrf2 protein-protein interaction","volume":"237","author":"Lee","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib91","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1021\/acs.jmedchem.2c00457","article-title":"Phenyl bis-sulfonamide Keap1-Nrf2 protein\u2013protein interaction inhibitors with an alternative binding mode","volume":"65","author":"Georgakopoulos","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115302","article-title":"Optimization of the C2 substituents on the 1,4-bis(arylsulfonamido)naphthalene-N,N\u2032-diacetic acid scaffold for better inhibition of Keap1-Nrf2 protein-protein interaction","volume":"252","author":"Abed","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104172","article-title":"Direct inhibition of Keap1-Nrf2 protein-protein interaction as a potential therapeutic strategy for Alzheimer's disease","volume":"103","author":"Sun","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib94","doi-asserted-by":"crossref","first-page":"8267","DOI":"10.1021\/acs.jmedchem.3c00686","article-title":"Fragment-based discovery of azocyclic alkyl naphthalenesulfonamides as Keap1-Nrf2 inhibitors for acute lung injury treatment","volume":"66","author":"Yan","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib95","doi-asserted-by":"crossref","first-page":"8289","DOI":"10.1021\/acs.jmedchem.2c00170","article-title":"Crystallography-guided optimizations of the Keap1\u2013Nrf2 inhibitors on the solvent exposed region: from symmetric to asymmetric naphthalenesulfonamides","volume":"65","author":"Liu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112734","article-title":"Discovery of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 protein-protein interaction inhibitors for inflammatory conditions","volume":"207","author":"Lu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib97","doi-asserted-by":"crossref","first-page":"28446","DOI":"10.1074\/jbc.M115.678136","article-title":"Characterization of RA839, a noncovalent small molecule binder to Keap1 and selective activator of Nrf2 signaling","volume":"290","author":"Winkel","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib98","doi-asserted-by":"crossref","first-page":"6796","DOI":"10.1021\/acs.jmedchem.9b00818","article-title":"Discovery of a potent Kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 (Keap1\u2013Nrf2) protein\u2013protein interaction inhibitor with natural proline structure as a cytoprotective agent against acetaminophen-induced hepatotoxicity","volume":"62","author":"Lu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117384","article-title":"Discovery of \u03b2-amino acid substituted naphthalene sulfonamide derivatives as potent Kelch-like ECH-associated protein 1\u2212nuclear factor erythroid 2-related factor 2 (Keap1\u2212Nrf2) protein\u2212protein interaction inhibitors for ulcerative colitis management","volume":"288","author":"Zhao","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib100","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1021\/acsmedchemlett.9b00631","article-title":"Synthesis and evaluation of noncovalent naphthalene-based KEAP1-NRF2 inhibitors","volume":"11","author":"Lazzara","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118485_bib101","series-title":"Direct Inhibitors of Keap1-Nrf2 Interaction as Antioxidant Inflammation Modulators","author":"Hu","year":"2013"},{"key":"10.1016\/j.ejmech.2025.118485_bib102","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1021\/jm4017174","article-title":"Rapid identification of Keap1\u2013Nrf2 small-molecule inhibitors through structure-based virtual screening and Hit-based substructure search","volume":"57","author":"Zhuang","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib103","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.freeradbiomed.2018.02.010","article-title":"Fragment-growing guided design of Keap1-Nrf2 protein-protein interaction inhibitors for targeting myocarditis","volume":"117","author":"Meng","year":"2018","journal-title":"Free Radical Biol. Med."},{"key":"10.1016\/j.ejmech.2025.118485_bib104","doi-asserted-by":"crossref","first-page":"11149","DOI":"10.1021\/acs.jmedchem.0c01116","article-title":"Design, synthesis, and structure\u2013activity relationships of indoline-based Kelch-like ECH-associated protein 1-Nuclear factor (Erythroid-Derived 2)-Like 2 (Keap1-Nrf2) protein\u2013protein interaction inhibitors","volume":"63","author":"Zhou","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib105","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1021\/acs.jmedchem.9b00279","article-title":"Structure\u2013activity and structure\u2013conformation relationships of aryl propionic acid inhibitors of the Kelch-like ECH-associated protein 1\/nuclear factor erythroid 2-related factor 2 (KEAP1\/NRF2) protein\u2013protein interaction","volume":"62","author":"Heightman","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib106","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1021\/acs.jmedchem.6b00228","article-title":"Monoacidic inhibitors of the Kelch-like ECH-associated protein 1: nuclear factor erythroid 2-related factor 2 (KEAP1:NRF2) protein\u2013protein interaction with high cell potency identified by fragment-based discovery","volume":"59","author":"Davies","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib107","doi-asserted-by":"crossref","first-page":"687","DOI":"10.34067\/KID.0004572021","article-title":"Novel Keap1-Nrf2 protein-protein interaction inhibitor UBE-1099 ameliorates progressive phenotype in Alport Syndrome mouse model","volume":"3","author":"Kaseda","year":"2022","journal-title":"Kidney360"},{"key":"10.1016\/j.ejmech.2025.118485_bib108","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1021\/acsmedchemlett.3c00067","article-title":"Methyl and fluorine effects in novel orally bioavailable Keap1\u2013Nrf2 PPI inhibitor","volume":"14","author":"Otake","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118485_bib109","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1021\/acs.jmedchem.3c02171","article-title":"Optimization efforts for identification of novel highly potent Keap1-Nrf2 protein\u2013protein interaction inhibitors","volume":"67","author":"Otake","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib110","doi-asserted-by":"crossref","first-page":"15949","DOI":"10.1021\/acs.jmedchem.1c01351","article-title":"Fragment-guided discovery of pyrazole carboxylic acid inhibitors of the kelch-like ECH-associated protein 1: nuclear factor erythroid 2 related factor 2 (KEAP1:NRF2) protein\u2212Protein interaction","volume":"64","author":"Norton","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib111","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1021\/acs.jmedchem.0c02094","article-title":"Deconstructing noncovalent Kelch-like ECH-associated protein 1 (Keap1) inhibitors into fragments to reconstruct new potent compounds","volume":"64","author":"Pallesen","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib112","doi-asserted-by":"crossref","first-page":"14481","DOI":"10.1021\/acs.jmedchem.2c00830","article-title":"Development of noncovalent small-molecule Keap1-Nrf2 inhibitors by fragment-based drug discovery","volume":"65","author":"Narayanan","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib113","doi-asserted-by":"crossref","first-page":"18828","DOI":"10.1021\/acs.jmedchem.4c01221","article-title":"Structure-guided conformational restriction leading to high-affinity, selective, and cell-active tetrahydroisoquinoline-based noncovalent Keap1-Nrf2 inhibitors","volume":"67","author":"Qin","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib114","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1021\/acs.jmedchem.0c01569","article-title":"Mining natural products for macrocycles to drug difficult targets","volume":"64","author":"Begnini","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib115","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1021\/acs.jmedchem.1c01975","article-title":"Importance of binding site hydration and flexibility revealed when optimizing a macrocyclic inhibitor of the Keap1\u2013Nrf2 protein\u2013protein interaction","volume":"65","author":"Begnini","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib116","article-title":"Selective disruption of NRF2-KEAP1 interaction leads to NASH resolution and reduction of liver fibrosis in mice","volume":"5","author":"Seedorf","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.ejmech.2025.118485_bib117","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1039\/C3MD00240C","article-title":"Novel protein\u2013protein interaction inhibitor of Nrf2\u2013Keap1 discovered by structure-based virtual screening","volume":"5","author":"Sun","year":"2014","journal-title":"Med. Chem. Commun"},{"key":"10.1016\/j.ejmech.2025.118485_bib118","doi-asserted-by":"crossref","first-page":"7186","DOI":"10.1021\/acs.jmedchem.5b00602","article-title":"Design, synthesis, and evaluation of triazole derivatives that induce Nrf2 dependent gene products and inhibit the Keap1\u2013Nrf2 protein\u2013protein interaction","volume":"58","author":"Bertrand","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib119","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/14756366.2018.1461856","article-title":"Identification of a novel small-molecule Keap1\u2013Nrf2 PPI inhibitor with cytoprotective effects on LPS-induced cardiomyopathy","volume":"33","author":"Jiang","year":"2018","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118485_bib120","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41586-020-2117-z","article-title":"An open-source drug discovery platform enables ultra-large virtual screens","volume":"580","author":"Gorgulla","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118485_bib121","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202508121","article-title":"Fragment-based drug discovery of novel high-affinity, selective, and anti-inflammatory inhibitors of the Keap1-Nrf2 protein-protein interaction","volume":"64","author":"Lin","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2025.118485_bib122","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.chembiol.2023.12.005","article-title":"Bivalent inhibitors of the BTB E3 ligase KEAP1 enable instant NRF2 activation to suppress acute inflammatory response","volume":"31","author":"Lu","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118485_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110446","article-title":"The mechanism of action and clinical value of PROTACs: a graphical review","volume":"99","author":"Graham","year":"2022","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejmech.2025.118485_bib124","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118485_bib125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118485_bib126","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1158\/1535-7163.MCT-23-0747","article-title":"PROTACs: current and future potential as a precision medicine strategy to combat cancer","volume":"23","author":"Rutherford","year":"2024","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.118485_bib127","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.chembiol.2022.08.003","article-title":"Exploring the target scope of KEAP1 E3 ligase-based PROTACs","volume":"29","author":"Du","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118485_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102783","article-title":"Development of KEAP1-targeting PROTAC and its antioxidant properties: in vitro and in vivo","volume":"64","author":"Park","year":"2023","journal-title":"Redox Biol."},{"key":"10.1016\/j.ejmech.2025.118485_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102552","article-title":"Design and characterization of a heterobifunctional degrader of KEAP1","volume":"59","author":"Chen","year":"2023","journal-title":"Redox Biol."},{"key":"10.1016\/j.ejmech.2025.118485_bib130","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1016\/j.apsb.2025.05.025","article-title":"Chemical knockdown of Keap1 and homoPROTAC-ing allergic rhinitis","volume":"15","author":"Yan","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.118485_bib131","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.freeradbiomed.2025.02.042","article-title":"A Keap1-recruiting BRD4 degrader offers a single-molecular polypharmacology approach for the treatment of metabolic dysfunction-associated steatohepatitis","volume":"232","author":"Zhang","year":"2025","journal-title":"Free Radic. Biol. Med."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:52:53Z","timestamp":1781326373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425012504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":131,"alternative-id":["S0223523425012504"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118485","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct small-molecule inhibitors of the Keap1-Nrf2 protein-protein interaction: Scaffold evolution, PROTAC strategies, and therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118485","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118485"}}